1. Home
  2. ICCC vs LOAN Comparison

ICCC vs LOAN Comparison

Compare ICCC & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • LOAN
  • Stock Information
  • Founded
  • ICCC 1982
  • LOAN 1989
  • Country
  • ICCC United States
  • LOAN United States
  • Employees
  • ICCC N/A
  • LOAN N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • LOAN Real Estate Investment Trusts
  • Sector
  • ICCC Health Care
  • LOAN Real Estate
  • Exchange
  • ICCC Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • ICCC 47.4M
  • LOAN 58.6M
  • IPO Year
  • ICCC 1987
  • LOAN 1999
  • Fundamental
  • Price
  • ICCC $5.20
  • LOAN $5.11
  • Analyst Decision
  • ICCC
  • LOAN
  • Analyst Count
  • ICCC 0
  • LOAN 0
  • Target Price
  • ICCC N/A
  • LOAN N/A
  • AVG Volume (30 Days)
  • ICCC 22.3K
  • LOAN 14.3K
  • Earning Date
  • ICCC 05-14-2025
  • LOAN 04-24-2025
  • Dividend Yield
  • ICCC N/A
  • LOAN 9.02%
  • EPS Growth
  • ICCC N/A
  • LOAN N/A
  • EPS
  • ICCC N/A
  • LOAN 0.48
  • Revenue
  • ICCC $26,493,169.00
  • LOAN $7,291,468.00
  • Revenue This Year
  • ICCC N/A
  • LOAN N/A
  • Revenue Next Year
  • ICCC N/A
  • LOAN $2.18
  • P/E Ratio
  • ICCC N/A
  • LOAN $10.63
  • Revenue Growth
  • ICCC 51.63
  • LOAN N/A
  • 52 Week Low
  • ICCC $3.34
  • LOAN $4.74
  • 52 Week High
  • ICCC $5.82
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 47.84
  • LOAN 43.00
  • Support Level
  • ICCC $5.01
  • LOAN $5.04
  • Resistance Level
  • ICCC $5.72
  • LOAN $5.20
  • Average True Range (ATR)
  • ICCC 0.18
  • LOAN 0.11
  • MACD
  • ICCC -0.04
  • LOAN 0.02
  • Stochastic Oscillator
  • ICCC 37.50
  • LOAN 21.24

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: